Myasthenia Gravis Myasthenia Gravis
Developments in Immunology

Myasthenia Gravis

Disease, Diagnosis and Management

    • $2,399.00
    • $2,399.00

Descripción editorial

Myasthenia Gravis: Disease, Diagnosis and Management is a comprehensive resource that explores recent advancements in diagnosing and treating Myasthenia Gravis, a rare autoimmune disease affecting the neuromuscular junction. With contributions from global experts, this book addresses the increasing prevalence of Myasthenia Gravis, reflecting the latest in diagnostic techniques and novel therapies such as complement inhibitors and FcRn antagonists. It aims to support healthcare professionals in delivering optimal care through evidence-based insights and patient-centered approaches. The book is divided into several chapters, beginning with an overview of the pathogenesis and immunoregulatory defects in Myasthenia Gravis. Subsequent chapters cover diagnostic methods, non-immunosuppressive treatments, and biological therapies targeting the immune system. Key topics include the role of intravenous immunoglobulin (IVIg) and plasma exchange (PLEX) in severe exacerbations, thymectomy, molecular mechanisms, and the potential of hematopoietic stem cell transplants. The book also delves into precision medicine, AI applications, clinical trial considerations, and novel therapeutics like anti-FcRn antibodies. Management strategies for ocular Myasthenia Gravis, and a holistic view of living with the disease are also discussed. Myasthenia Gravis: Disease, Diagnosis and Management is invaluable for healthcare providers, physicians, immunologists, ophthalmologists, rheumatologists, physical therapists, pharmacists, and translators. It offers a modern guide to understanding and managing Myasthenia Gravis, integrating clinical expertise with the latest research to improve patient outcomes.

- Explores pathogenesis, diagnosis, and treatment options for Myasthenia Gravis, providing a complete understanding of the disease

- Highlights cutting-edge therapies like complement inhibitors and FcRn antagonists for improved patient outcomes

- Ensures authoritative and up-to-date information contributed by global experts

- Offers evidence-based strategies for healthcare professionals to optimize Myasthenia Gravis management

- Integrates clinical expertise with patient-centered care for a well-rounded perspective on disease management

GÉNERO
Técnicos y profesionales
PUBLICADO
2025
3 de diciembre
IDIOMA
EN
Inglés
EXTENSIÓN
350
Páginas
EDITORIAL
Academic Press
VENDEDOR
Elsevier Ltd.
TAMAÑO
33.8
MB
Cystic Fibrosis Cystic Fibrosis
2026
Two Sides of Nanovaccines and Nanomedicines in Cancer Treatments Two Sides of Nanovaccines and Nanomedicines in Cancer Treatments
2026
Revolutionizing Cancer Treatment Revolutionizing Cancer Treatment
2026
Nanocarriers in Prostate Cancer Nanocarriers in Prostate Cancer
2025
Artificial Intelligence in Patient Counselling Artificial Intelligence in Patient Counselling
2025
Synthetic Biology and its Consequences in Present Healthcare Synthetic Biology and its Consequences in Present Healthcare
2025
Metabolites as Signals in Immunity and Inflammation Metabolites as Signals in Immunity and Inflammation
2025
Glycobiology of the Immune System and Disease Glycobiology of the Immune System and Disease
2026
Vaccinology and Methods in Vaccine Research Vaccinology and Methods in Vaccine Research
2022
Visceral Leishmaniasis Visceral Leishmaniasis
2021